http://www.futureprescriber.co.uk Future Prescriber current issue RSS Feed http://www.futureprescriber.co.uk/details/journalArticle/1311531/Raising_HDLC_through_cholesteryl_ester_transfer_protein_inhibition.html Abstract Plasma concentrations of high‐density lipoprotein cholesterol (HDL‐C) and its major protein component apolipoprotein (apo) A‐I are strongly inversely correlated with cardiovascular risk, leading to the notion that therapy to increase HDL‐C and apoA‐I concentrations would be antiatherosclerotic and protective against cardiovascular disease (CVD) events.1,2 In this article, the authors discuss how inhibition of... 2011-08-08T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/1073501/Fingolimod_new_oral_treatment_for_multiple_sclerosis.html Abstract Fingolimod, a sphingosine‐1‐phosphate receptor modulator, is a novel oral treatment for multiple sclerosis. In this Drug profile the author reviews its mode of action, likely positioning and the advantages that it might offer in terms of clinical management of multiple sclerosis, and begins by setting the treatment context. 2011-05-31T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/986059/Tapentadol_a_novel_analgesic_for_treating_moderate_to_severe_pain.html Abstract Pain management in primary care relies on a combination of pharmacological and nonpharmacological treatments. Opioid analgesics are widely employed but long‐term use can lead to side‐effects and issues including drug tolerance. In this article, Anthony Dickenson considers tapentadol, the first in a new class of centrally acting analgesics with two mechanisms of action in a single molecule and the promise of fewer... 2011-01-20T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/759167/The_promise_of_future_treatments_in_AF_is_it_all_over_for_warfarin.html Abstract Aspirin and warfarin are currently the only treatment options for patients presenting with atrial fibrillation at risk of stroke. New oral direct thrombin inhibitors may offer an additional choice or viable alternative. Here we consider their potential role with a focus on dabigatran. Copyright © 2010 John Wiley & Sons, Ltd. 2010-07-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/589011/New_directions_in_cancer_therapy__HDAC_inhibitors.html Abstract The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non‐Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve... 2010-03-15T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/589013/New_directions_in_cancer_therapy__HDAC_inhibitors.html Abstract The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non‐Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve... 2010-03-15T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520591/AntiTNFalpha_drugs__moving_into_the_mainstream.html Abstract Anti‐TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease‐modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti‐TNF‐alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley & Sons, Ltd. ... 2009-12-24T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520589/AntiTNFalpha_drugs__moving_into_the_mainstream.html Abstract Anti‐TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease‐modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti‐TNF‐alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley & Sons, Ltd. ... 2009-12-24T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/303725/Management_of_prostate_cancer_future_treatment_approaches.html Abstract Prostate cancer is now the most commonly diagnosed cancer in men. This may reflect a true increase in the incidence of the disease, but a component of it is certainly related to increased detection rates due to opportunistic prostate specific antigen (PSA) testing. In this article, Professor Malcolm Mason reviews the current treatment of prostate cancer and considers promising future treatment options, including the... 2009-08-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/303733/Management_of_prostate_cancer_future_treatment_approaches.html Abstract Prostate cancer is now the most commonly diagnosed cancer in men. This may reflect a true increase in the incidence of the disease, but a component of it is certainly related to increased detection rates due to opportunistic prostate specific antigen (PSA) testing. In this article, Professor Malcolm Mason reviews the current treatment of prostate cancer and considers promising future treatment options, including the... 2009-08-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/186572/Highcost_drugs__the_Welsh_perspective.html 2009-04-28T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/162179/Tocilizumab__IL6_inhibition_for_the_treatment_of_rheumatoid_arthritis.html Abstract Affecting approximately 400 000 people in England and Wales,1 rheumatoid arthritis (RA) creates a considerable economic burden. NICE estimates that five years after diagnosis, 40% of RA patients will be incapable of work.1 Some treatment options for RA look to control inflammation in order to rein in the disease. Interleukin‐6 (IL‐6) invokes inflammation via TNF‐α, although the reason for this is unknown. Some researchers are beginning... 2009-02-26T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/119141/Can_NICE_do_its_job.html 2008-08-08T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/119154/Use_of_unlicensed_drugs_what_are_the_issues.html 2008-08-08T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/119147/Primary_prevention_for_all.html 2008-07-07T00:00:00Z